Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210554 | 0.85 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL5722254 | 0.84 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL9860211 | 0.83 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL1186911 | 0.82 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL862849 | 0.81 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL225085 | 0.80 | KMT2A (0.65) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL6202908 | 0.80 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL862848 | 0.80 | KMT2A (0.49) | MEN1KMT2ALMNANPC1PDE4B | |
| SCHEMBL863077 | 0.80 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL26452181 | 0.79 | PARP10 (0.58) | MEN1KMT2ASMN1; SMN2LMNAPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009091813-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181952-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181952-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA2, CHRNA6 | MEN1 3921/4885KMT2A 2527/4885SMN1; SMN2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.